Sheppard’s Private Equity team represented global private equity firm ARCHIMED in its acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific.
Biomark Scientific, an innovative microfluidics technology tools provider specializing in high-throughput and multi-assay genomics systems, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform. The next-generation Biomark X9 system is the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple types of genomic assay readouts in a single run using patented integrated fluidic circuits.
The Sheppard deal team was led by Valerie Demont, Vinnie Buehler and Karl Buhler and included Christie Alvarez, Edouard Goguillon and Chelsea Lim. Invaluable assistance was provided by Greg Berk, Townsend Bourne, Dmitriy Chelnitsky, Brian Egan, Rob Gorzelany, Sean Kirby, Carolyn Metnick, Michael Orlando, Niya Tang, Olivier Theard, Dimitris Vallindas, Reid Whitten, Daniel Yannuzzi, Sally Elshihabi, Julien Blanquart, Brandon Buck, Tracy Chau, Weiwei Chen, Alyanna Gallo, Tiana Garbett, Erin Hausladen, Siyi Shen, Isaiah Smith, Tina Watson and Michael Weisshar.
Read the full press release here.